HIV treatment has changed enough that many people now have a choice not only of medicines, but of how treatment fits into daily life. A once-daily tablet works well for most people. For some who already have the virus under control, injections can replace daily pills. And for people with HIV that resists several drugs, newer drug classes offer ways to build a working regimen.
The goal hasn’t changed: suppress HIV, protect the immune system, and keep treatment sustainable for years. A regimen is only an advance if it works against a person’s virus and they can keep taking it. That makes resistance history, other health conditions, side effects, and reliable access to care as important as dosing convenience.
Antiretroviral therapy is still the foundation
Antiretroviral therapy, or ART, uses drugs that interrupt different steps in HIV’s life cycle. Treatment is recommended for everyone with HIV and should begin as soon as possible after diagnosis. The aim is lasting viral suppression, not simply an improved lab result at the next visit.
For most adults starting treatment, U.S. guidelines recommend a regimen built around bictegravir or dolutegravir, both integrase inhibitors. One common single-tablet option is Biktarvy, which combines bictegravir, emtricitabine, and tenofovir alafenamide. Dolutegravir can also be paired with two other drugs. Dovato combines dolutegravir with lamivudine in one tablet; it is a recommended initial option when testing has ruled out relevant resistance and chronic hepatitis B infection. Some people need a different starting regimen, particularly if they acquired HIV after using long-acting cabotegravir for prevention and integrase resistance has not been ruled out.
This is a shift from the idea that every effective HIV regimen must contain three drugs. It does not mean fewer drugs are always better. Before choosing or changing treatment, clinicians review viral load, hepatitis B status, medication interactions, pregnancy considerations, kidney function, and past resistance results.
Sustained suppression has a benefit beyond personal health. A person who takes ART and maintains a viral load below 200 copies/mL does not sexually transmit HIV. This is known as undetectable equals untransmittable, or U=U. It depends on staying in care and maintaining suppression; it does not mean HIV has been cured.
Long-acting treatment offers a different routine
Cabenuva combines injectable cabotegravir and rilpivirine. It can replace oral ART for eligible people whose HIV is already suppressed on a stable regimen and who have no known or suspected resistance to either drug. Injections are given monthly or every two months. The oral lead-in used to check tolerability is optional, not mandatory.
For someone who dislikes a daily reminder of HIV or needs greater privacy at home, that trade may be worthwhile. But injections replace pill-taking with scheduled clinic visits. Missed appointments need a plan: drug levels can persist after an injection while falling too low to control HIV, creating an opportunity for resistance. Injection-site reactions and interactions with other medicines also matter.
Cabenuva is not a simple substitute for someone whose daily treatment is failing. The usual approach is to identify why suppression was lost and regain control with an effective regimen before considering a switch. Research on injections for people who have had trouble taking pills is encouraging, but it has involved substantial support to achieve suppression first.
New drug classes serve different needs
Some are established treatments, and one is used for prevention rather than treatment. The distinction matters most with lenacapavir: the same active drug has different uses under different products.
| Option | Where it fits |
|---|---|
| Sunlenca (lenacapavir) | A capsid inhibitor given by injection every six months, with other antiretroviral drugs, for certain heavily treatment-experienced adults with multidrug-resistant HIV whose regimen is failing. |
| Trogarzo (ibalizumab) and Rukobia (fostemsavir) | Drugs with different mechanisms that specialists may use when constructing regimens for heavily treatment-experienced people with resistant HIV. |
| Idvynso (doravirine/islatravir) | A daily, two-drug tablet approved in 2026 as a switch option for eligible adults whose HIV is already suppressed. |
| Bixlenvo (bictegravir/lenacapavir) | A daily, two-drug tablet approved in August 2026 to replace treatment in eligible adults whose HIV is already suppressed. |
Sunlenca’s six-month injection is not a complete HIV treatment. Its companion drugs still have to be effective and taken as prescribed. If a person cannot maintain the rest of the regimen, resistance to lenacapavir can develop. That is why a long dosing interval for one drug should not be mistaken for a twice-yearly complete treatment.
The newer tablets meet a different need. Idvynso is an option for selected adults with ongoing suppression and no prior treatment failure or resistance that would undermine the regimen. Bixlenvo is also a switch regimen, not an initial treatment or a six-month injection. Its dosing begins with a two-day initiation regimen that includes oral Sunlenca, followed by one Bixlenvo tablet daily. Neither new tablet removes the need to check treatment history and drug interactions.
When a viral load rises despite treatment, the useful next step is a careful review—not an automatic switch to the newest drug. Clinicians assess missed doses, access problems, interactions, and resistance, then build a regimen with enough active drugs. This is especially important for someone who has already used several treatment classes.
Tailored care protects long-term health
Good HIV care looks beyond the viral load. Kidney disease, cardiovascular risk, diabetes, hepatitis B, mental health, and the medicines used to treat them can all affect the safest ART choice.
For example, tenofovir disoproxil fumarate can be a poor fit for some people with kidney disease; tenofovir alafenamide often has more favorable effects on kidney measures and bone density, though it is not suitable for every situation. Clinicians may consider alternatives to abacavir for someone with substantial cardiovascular risk. Hepatitis B requires particular care: changing to a two-drug HIV regimen without an effective hepatitis B medicine can leave the hepatitis untreated.
Age adds another layer. An older adult may take medicines for blood pressure, cholesterol, or other conditions, as well as supplements. Reviewing the full medication list and past resistance results helps avoid interactions without sacrificing HIV control. Preventive care—such as vaccinations, cancer screening, and assessment of heart risk—also remains important after viral suppression.
Cost can determine whether a plan is workable. Coverage for a medicine, clinic-administered injections, and the visits themselves should be checked before a switch. The AIDS Drug Assistance Program can help eligible people with HIV obtain medication; eligibility and covered drugs vary by state.
PrEP and PEP prevent HIV; they do not treat it
Pre-exposure prophylaxis, or PrEP, is for people who do not have HIV and want protection before possible exposure. Options include daily oral medication and long-acting injections. Cabotegravir PrEP, sold as Apretude, is given every two months after initiation. Since 2025, lenacapavir PrEP, sold as Yeztugo, has offered a six-month injection option for eligible people. Yeztugo and the Sunlenca treatment regimen contain the same active drug but have different purposes; PrEP is not a treatment for someone diagnosed with HIV. HIV testing before and during PrEP is essential.
Post-exposure prophylaxis, or PEP, is a time-sensitive course of ART after a possible exposure. It should be assessed and, when indicated, started as soon as possible—no later than 72 hours—and taken for 28 days. CDC’s preferred PEP regimens include bictegravir/emtricitabine/tenofovir alafenamide or a dolutegravir-based combination. Anyone concerned about a recent exposure should seek urgent care rather than wait for a routine HIV appointment.
Children and older adults need age-specific plans
Children need formulations and doses suited to their weight and development, with adjustments as they grow. Dispersible dolutegravir tablets are one option for young children; pediatric guidelines describe their use alongside other antiretroviral drugs. Dovato is an option for eligible adolescents aged 12 or older who weigh at least 55 pounds, but it is not a general substitute for a child’s weight-based regimen.
Older adults, meanwhile, may benefit less from a novel formulation than from a careful check for interactions, kidney or bone effects, and medicines they no longer need. At either end of the age range, the best innovation is often a treatment plan that can be followed reliably as circumstances change.
Cure research is promising, but treatment cannot wait for it
ART suppresses HIV but does not clear the latent virus that can remain in cells. Researchers are studying ways to achieve lasting remission without ongoing treatment, including broadly neutralizing antibodies, immune-based approaches, and gene editing. These remain research strategies, not alternatives to prescribed ART. NIAID’s HIV cure research focuses in part on understanding and targeting that persistent viral reservoir.
For a person living with HIV, the practical decision is closer at hand: choose an effective regimen, make sure it fits everyday life, and revisit it when health needs or treatment goals change. Longer-acting drugs and new combinations have expanded those choices. Lasting viral suppression remains the measure that makes them meaningful.
Disclaimer
This article provides general health information and is not a substitute for advice from an HIV care professional. Do not start, stop, or change HIV medication without discussing it with your care team.